What share price and notional share amounts were used for the GSK deferred award payouts?

All three payouts used a GSK ordinary share price of £21.68. Luke Miels and Deborah Waterhouse each had 24,979.493 notional shares, while Regis Simard had 12,489.746 notional shares, with cash paid instead of issuing actual shares, subject to tax withholding.

Deferred awards pay out to GSK (NYSE: GSK) senior leadership

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

6-K

Rhea-AI Filing Summary

GSK plc filed a Form 6-K detailing cash settlements of deferred incentive awards for three senior executives under the GlaxoSmithKline Deferred Investment Award Programme. The final 25% of awards granted on 10 February 2021 vested on 10 February 2026, based on GSK ordinary shares.

Chief Executive Officer Luke Miels and CEO, ViiV Healthcare and President, Global Health, GSK Deborah Waterhouse will each receive a cash payment of £541,555.40, reflecting 24,979.493 notional ordinary shares at £21.68. Regis Simard, President, Global Supply Chain, will receive £270,777.70 in cash in respect of 12,489.746 notional ordinary shares, also priced at £21.68, in each case before tax withholding.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 02/11/2026 - 11:55 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Luke Miels
b)	Position/status	Chief Executive Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Following the vesting on 10 February 2026 of the final 25% of an award made on 10 February 2021 under the GlaxoSmithKline Deferred Investment Award Programme, Luke Miels will receive a cash payment of £541,555.40 less applicable tax withholding in respect of 24,979.493 notional Ordinary Shares.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£21.68	24,979.493

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-02-10
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Following the vesting on 10 February 2026 of the final 25% of an award made on 10 February 2021 under the GlaxoSmithKline Deferred Investment Award Programme, Regis Simard will receive a cash payment of £270,777.70 less applicable tax withholding in respect of 12,489.746 notional Ordinary Shares.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£21.68	12,489.746

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-02-10
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Deborah Waterhouse
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Following the vesting on 10 February 2026 of the final 25% of an award made on 10 February 2021 under the GlaxoSmithKline Deferred Investment Award Programme, Deborah Waterhouse will receive a cash payment of £541,555.40 less applicable tax withholding in respect of 24,979.493 notional Ordinary Shares.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£21.68	24,979.493

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-02-10
f)	Place of the transaction	N/A

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

	GSK plc
	(Registrant)

Date: February 11, 2026

	By:/s/ VICTORIA WHYTE --------------------------

	Victoria Whyte
	Authorised Signatory for and on
	behalf of GSK plc

Source: View Original Filing on SEC EDGAR

FAQ

What executive compensation transactions did GSK (GSK) disclose in this Form 6-K?

GSK disclosed cash settlements of vested deferred investment awards for three senior executives. The vesting covered the final 25% of awards granted in February 2021, settled in cash based on the value of GSK ordinary shares on 10 February 2026.

How much cash will GSK CEO Luke Miels receive from the deferred award vesting?

Luke Miels will receive a cash payment of £541,555.40 before tax withholding. This amount corresponds to 24,979.493 notional GSK ordinary shares valued at £21.68 each, reflecting the final 25% vesting of his February 2021 deferred investment award.

What payout was reported for GSK executive Regis Simard in this filing?

Regis Simard will receive a cash payment of £270,777.70 before tax withholding. The payment is calculated on 12,489.746 notional GSK ordinary shares at £21.68 per share, representing the final 25% vesting of his February 2021 deferred investment award.

What compensation did Deborah Waterhouse of GSK receive from the deferred award vesting?

Deborah Waterhouse will receive a cash payment of £541,555.40 before tax withholding. This is based on 24,979.493 notional GSK ordinary shares at £21.68 each, reflecting the final 25% vesting of a deferred investment award granted on 10 February 2021.

On what date did the GSK deferred investment awards vest for these executives?

The final 25% of the GlaxoSmithKline Deferred Investment Award Programme grants vested on 10 February 2026. These awards were originally made on 10 February 2021 and were settled in cash based on the value of GSK ordinary shares on the vesting date.